FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377041731> ?p ?o ?g. }

• W4377041731 endingPage "2303" @default.
• W4377041731 startingPage "2302" @default.
• W4377041731 abstract "Dear Editor, In a recent report by the World Health Organization (WHO), there are 2.2 billion cases of visual impairment globally, of which 5.1% contribute to blindness due to corneal causes. India alone contributes to 21% of the worldwide incidence of visual impairment and 20% of the incidence of blindness.[1] Corneal infection caused by fungi such as Fusarium, Aspergillus, and Candida, are difficult to treat and has now become a significant challenge for cornea specialists. Natamycin is the drug of choice for fungal keratitis and is classified as a class IV drug by the Food and Drug Administration’s (FDA) Biopharmaceutics Classification System (BCS).[2] It is poorly water-soluble and permeable and is also the only approved drug by the FDA to treat fungal keratitis. It is available in 5% strength as a suspension. The bioavailability of natamycin is only 5%, and the bioavailability further decreases due to the tear turnover rate and nasolacrimal drainage. Moreover, poor patient compliance and treatment failure can lead to corneal blindness due to formulation-like suspension and frequent dosing (every hour or 2 h for several days)-related problems.[3] The US Food and Drug Administration (USFDA) classifies hydroxypropyl b-cyclodextrin (HPbCD) as an inactive ingredient and uses it as a pharmaceutical excipient. It is known that CD can move class IV drugs to class I drugs, which are highly soluble and highly permeable, by forming a complex. Considering the advantages of CD and the need for a better topical formulation of natamycin to reduce the dose frequency and increase bioavailability, there was a need to prepare a better water-soluble formulation of natamycin. This gave birth to natasaol, which is formed when natamycin is complexed with CD following its pharmaceutical and pharmacological assessment. A stable, water-soluble natamycin formulation (natasol 1%) is prepared by forming an inclusion complex with HPbCD. The characterization of complex natamycin with CD is performed by Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC). The topical natasol, 1% formulation, has also been tested for stability at various conditions relating to the use by the patients, such as in white light at room temperature, in a dark room at 25°C, and by opening and closing the vial once a day at 4°C. Single and multi-dose trans-corneal permeation of natasol 1% in comparison with 5% natamycin suspension has also been assessed in New Zealand Albino rabbits. A sterile, unpreserved, ready-to-use, water-soluble natamycin (natasol 0.01%) for intrastromal injection has been developed at AIIMS, New Delhi, using the Association for Research in Vision and Ophthalmology (ARVO) guidelines. Both topical natasol (1%) and intrastromal natasol (0.01%) have been assessed for ocular toxicity. FTIR and DSC analyses demonstrate that when natamycin is complexed with HPbCD, it is protected against degradation under various stability circumstances. Natamycin complexed with HPbCD demonstrated that HPbCD prevents natamycin photodegradation in the natasol 1% formulation. Natasol 1% is a yellow color macroscopic formulation. free from any suspended particles compared to the marketed formulation of 5% natamycin suspension. Trans-corneal permeation of a single-dose study shows that natamycin 5% suspension reaches Cmax at 2 h, whereas natasol 1% reaches Cmax at 1 h. Furthermore, natasol 1% intraocular concentration was higher in the fourth and sixth hours compared to the natamycin 5% suspension. The steady-state pharmacokinetics was revealed by multi-dose kinetics following hourly and two-hourly dosing regimens. Natasol (1%) and intrastromal formulation (0.01%) did not show any ocular toxicity in the tested animals.[4] Natamycin is a poorly water-soluble drug (0.052 mg/mL), thus it can only be developed as a suspension. The coarse particles in the suspension and tear turnover rate decrease the bioavailability of the drug. HPbCD shows characteristic peaks at 1033, 1117, and 1157 in FTIR, and peaks of natamycin disappeared at 1002.69, 1064.97, and 1105.15 after complexation. Furthermore, the appearance of a melting peak at 171 confirms the complex formation. For the natamycin concentration, this study used the sensitive High-performance liquid chromatography (HPLC) method at various steps of the formulation development, and for the quantification of the natamycin formulation, the Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) method was developed. Saluja et al.,[5] in their study, found that intrastromal natasol increases drug delivery at the injection site for a more extended period and improves microbiological cure. Natasol, being a preservative-free formulation, enhances and facilitates epithelial healing and helps in better patient monitoring. The authors suggested that intrastromal natasol can be the drug of choice for intrastromal injection and can soon replace natamycin, which is slower-acting and has the potential to improve topical drug frequency. The pharmaceutical excipient components of natasol have been labeled as Generally Recognized as Safe (GRAS) and inactive by the FDA for human use. However, complications such as cataracts and deep stromal vascularization must be kept in mind while using the new formulation. A direct correlation between drug use and complication is difficult to comprehend as severe inflammation can be an additive bias. To sum up, natasol, as a novel pharmacological solution, holds promise as an adjunctive agent for the management of recalcitrant fungal keratitis. However, larger studies will be needed to determine its efficacy due to regional differences in microbiological profiles and as a primary drug of choice for fungal keratitis. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest." @default.
• W4377041731 created "2023-05-19" @default.
• W4377041731 creator A5072348328 @default.
• W4377041731 creator A5089736378 @default.
• W4377041731 creator A5091974907 @default.
• W4377041731 date "2023-05-01" @default.
• W4377041731 modified "2023-09-26" @default.
• W4377041731 title "Natasol as a future management option to combat fungal keratitis" @default.
• W4377041731 cites W2064185190 @default.
• W4377041731 cites W3145165607 @default.
• W4377041731 cites W3155874844 @default.
• W4377041731 cites W3204248400 @default.
• W4377041731 cites W4286498522 @default.
• W4377041731 doi "https://doi.org/10.4103/ijo.ijo_190_23" @default.
• W4377041731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37202986" @default.
• W4377041731 hasPublicationYear "2023" @default.
• W4377041731 type Work @default.
• W4377041731 citedByCount "0" @default.
• W4377041731 crossrefType "journal-article" @default.
• W4377041731 hasAuthorship W4377041731A5072348328 @default.
• W4377041731 hasAuthorship W4377041731A5089736378 @default.
• W4377041731 hasAuthorship W4377041731A5091974907 @default.
• W4377041731 hasBestOaLocation W43770417311 @default.
• W4377041731 hasConcept C118487528 @default.
• W4377041731 hasConcept C119767625 @default.
• W4377041731 hasConcept C126322002 @default.
• W4377041731 hasConcept C142724271 @default.
• W4377041731 hasConcept C16005928 @default.
• W4377041731 hasConcept C2776042228 @default.
• W4377041731 hasConcept C2776079991 @default.
• W4377041731 hasConcept C2776882836 @default.
• W4377041731 hasConcept C2778560704 @default.
• W4377041731 hasConcept C2779117757 @default.
• W4377041731 hasConcept C2780035454 @default.
• W4377041731 hasConcept C2780870513 @default.
• W4377041731 hasConcept C2780929884 @default.
• W4377041731 hasConcept C71924100 @default.
• W4377041731 hasConcept C98274493 @default.
• W4377041731 hasConceptScore W4377041731C118487528 @default.
• W4377041731 hasConceptScore W4377041731C119767625 @default.
• W4377041731 hasConceptScore W4377041731C126322002 @default.
• W4377041731 hasConceptScore W4377041731C142724271 @default.
• W4377041731 hasConceptScore W4377041731C16005928 @default.
• W4377041731 hasConceptScore W4377041731C2776042228 @default.
• W4377041731 hasConceptScore W4377041731C2776079991 @default.
• W4377041731 hasConceptScore W4377041731C2776882836 @default.
• W4377041731 hasConceptScore W4377041731C2778560704 @default.
• W4377041731 hasConceptScore W4377041731C2779117757 @default.
• W4377041731 hasConceptScore W4377041731C2780035454 @default.
• W4377041731 hasConceptScore W4377041731C2780870513 @default.
• W4377041731 hasConceptScore W4377041731C2780929884 @default.
• W4377041731 hasConceptScore W4377041731C71924100 @default.
• W4377041731 hasConceptScore W4377041731C98274493 @default.
• W4377041731 hasIssue "5" @default.
• W4377041731 hasLocation W43770417311 @default.
• W4377041731 hasLocation W43770417312 @default.
• W4377041731 hasLocation W43770417313 @default.
• W4377041731 hasLocation W43770417314 @default.
• W4377041731 hasOpenAccess W4377041731 @default.
• W4377041731 hasPrimaryLocation W43770417311 @default.
• W4377041731 hasRelatedWork W1983462777 @default.
• W4377041731 hasRelatedWork W2031668705 @default.
• W4377041731 hasRelatedWork W2375453913 @default.
• W4377041731 hasRelatedWork W2379400586 @default.
• W4377041731 hasRelatedWork W2399751942 @default.
• W4377041731 hasRelatedWork W4211007882 @default.
• W4377041731 hasRelatedWork W4280539512 @default.
• W4377041731 hasRelatedWork W4303832790 @default.
• W4377041731 hasRelatedWork W4312366488 @default.
• W4377041731 hasRelatedWork W4313424427 @default.
• W4377041731 hasVolume "71" @default.
• W4377041731 isParatext "false" @default.
• W4377041731 isRetracted "false" @default.
• W4377041731 workType "article" @default.